Drug Trial Radar · NCT07282210
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2029
Study completion Oct 2031
Sponsor
- Lead sponsor
- Biossil Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SIL-8301 (senicapoc) is being developed for the chronic treatment of patients with sickle cell disease in both adults and children. The purpose of this study is to compare the effects of senicapoc to placebo in patients with sickle cell disease that have had fewer than 2 acute sickle-related painful crises per year over the preceding 2 years, and have a predominantly hemolytic phenotype, defined as evidence of ongoing hemolysis and a baseline Hb of 9.5 g/dL or less, despite receiving hydroxyurea (an oral drug used for treatment of sickle cell disease) as standard of care. Participants will take senicapoc or matching placebo daily and continue on hydroxyurea as prescribed for up to 24 weeks. Eligible participants that complete the 24 weeks will have an opportunity to receive senicapoc for up to 2 years in an optional open label extension.
Conditions
- Sickle Cell Disease
- Sickle Cell Anaemia
- Sickle Cell Anemia
Interventions
SenicapocDrug
10 mg tablets; administered at a loading dose of 20 mg twice daily for 4 days, followed by a maintenance dose of 10 mg once daily for up to 24 weeks
PlaceboDrug
Tablets similar in size and color; matching administration schedule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hb response rateTime frame: 24 Weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
The Hospital for Sick Children
Toronto, Ontario, Canada · Recruiting
University Health Network, Toronto General Hospital
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada · Recruiting
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.